Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe.

ABSTRACT:

Purpose

This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per 10 000 first treatments.

Methods

Cohort study of IV iron new users, captured mostly through pharmacy ambulatory dispensing, from populations covered by health and administrative data sources in five European countries from 1999 to 2017. Anaphylaxis events were identified through an algorithm that used parenteral penicillin as a positive control.

Results

A total of 304 210 patients with a first IV iron treatment (6367 iron dextran), among whom 13-16 anaphylaxis cases were ide

SUBMITTER: Fortuny J 

PROVIDER: S-EPMC8457074 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature